Aromek 2.5 mg Ingredients and Usage

The active ingredient is Letrozole, a non-steroidal drug. The 2.5 mg tablet is taken orally once daily.

Aromek is clinically indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women in several settings:

• Adjuvant Treatment: As a first-line therapy for early breast cancer following initial surgery.
• Extended Adjuvant Treatment: For patients who have completed standard adjuvant therapy (e.g., 5 years of Tamoxifen) to reduce the risk of late recurrence.
• First-Line Treatment: For advanced breast cancer (locally advanced or metastatic).
• Ovulation Induction (Off-label): Used by specialists to induce ovulation in certain women with polycystic ovary syndrome (PCOS).

How Does Aromek Work?

Aromek (Letrozole) is a potent aromatase inhibitor that effectively blocks the source of estrogen production in postmenopausal women. Its mechanism is as follows:

1. Aromatase Inhibition: It selectively and competitively inhibits the enzyme Aromatase. This enzyme is responsible for the final step in the biosynthesis of estrogens, converting androgens (primarily produced by the adrenal glands) into estrogens (Estrone and Estradiol) in non-ovarian tissues.
2. Estrogen Suppression: By blocking Aromatase, Letrozole causes a profound (>98%) reduction in circulating estrogen levels.
3. Tumor Regression: This severe reduction in estrogen “starves” the hormone receptor-positive (ER+) cancer cells, preventing their growth and proliferation, which leads to tumor regression and reduces disease progression.

Aromek 2.5 mg Side Effects and Warnings

The side effects of Aromek are primarily related to the significant reduction in estrogen levels, mimicking menopausal symptoms. Common side effects include:

• Hot Flashes (very common)
• Joint Pain (Arthralgia) and Muscle Pain
• Fatigue, Dizziness, and Headache
• Increased sweating (Hyperhidrosis)

Serious Warnings and Precautions:

Osteoporosis and Fractures: The reduction in estrogen accelerates bone density loss, significantly increasing the risk of Osteoporosis and subsequent fractures (hip, spine). Regular bone mineral density (BMD) screening (e.g., DEXA scans) and calcium/Vitamin D supplementation are often recommended.

Cardiovascular Risk: An increased risk of hypercholesterolemia (high cholesterol) and potential cardiovascular events (e.g., stroke, heart attack) may be associated with treatment.

Dizziness/Driving: Since the drug can cause dizziness or somnolence, patients should be cautious when driving or operating machinery.

Contraindication: Aromek is contraindicated in premenopausal women (unless receiving ovarian suppression), pregnant or breastfeeding women, and those with severe hypersensitivity to Letrozole.

Aromek 2.5 mg Storage Conditions

Aromek Tablets should be stored under standard conditions to ensure efficacy:

• Store the tablets at controlled room temperature, typically between 20°C and 25°C (68°F and 77°F).
• Keep the tablets in the original blister pack or container to protect them from moisture and light.
• Keep out of the reach of children.
• Take the medicine at the same time each day, with or without food.